Thomas M. Caparrotta

1.4k citations

23 papers · 583 indexed · h-index 16

Pharmacology top 5%
- Drug-Induced Hepatotoxicity and Protection 3
Endocrinology, Diabetes and Metabolism top 5%
- Diabetes Management and Research 11
- Diabetes Treatment and Management 9
Emergency Medicine top 10%
- Poisoning and overdose treatments 3
Geriatrics and Gerontology
Hepatology
Genetics
- Diabetes and associated disorders 4
Molecular Biology
- Metabolism, Diabetes, and Cancer 4
Epidemiology
- Chronic Disease Management Strategies 3
Infectious Diseases
- COVID-19 Clinical Research Studies 3

Co-authors: James W. Dear Helen M. Colhoun Marc Evans John Paul Thompson James Coulson Daniel J. Antoine Paul McKeigue Sarah H. Wild
Cited by: Pharmacology Endocrinology, Diabetes and Metabolism Emergency Medicine
Journals: Circulation (1 paper)PLoS ONE (1 paper)Diabetes Care (3 papers)
Partner nations: United Kingdom Canada United States

In The Last Decade

Thomas M. Caparrotta

23 papers receiving 568 citations

Peers

Countries citing papers authored by Thomas M. Caparrotta

Since Specialization

Citations

This map shows the geographic impact of Thomas M. Caparrotta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas M. Caparrotta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas M. Caparrotta more than expected).

Fields of papers citing papers by Thomas M. Caparrotta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas M. Caparrotta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas M. Caparrotta. The network helps show where Thomas M. Caparrotta may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Thomas M. Caparrotta, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas M. Caparrotta Line = papers co-authored together Thomas M. Caparrotta links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Impact of COVID-19 and Non-COVID-19 Hospitalized Pneumonia on Longer-Term Cardiovascular Mortality in People With Type 2 Diabetes: A Nationwide Prospective Cohort Study From Scotland Diabetes Care ·Stuart J. McGurnaghan,Paul McKeigue,Luke A. K. Blackbourn,Joseph Mellor,Thomas M. Caparrotta,Naveed Sattar,Brian Kennon,David McAllister,Sarah H. Wild,Helen M. Colhoun	2024	3
2	UMOD Genotype-Blinded Trial of Ambulatory Blood Pressure Response to Torasemide Hypertension ·Linsay McCallum,Stefanie Lip,Alex McConnachie,Katriona Brooksbank,I. MacIntyre,Alex S. F. Doney,Andrea Llano,Alisha Aman,Thomas M. Caparrotta,Gareth Ingram,Isla S. Mackenzie,Anna F. Dominiczak,Thomas M. MacDonald,David J. Webb,Sandosh Padmanabhan	2024	10
3	Paracetamol use in adults BMJ ·Thomas M. Caparrotta,Emma Carduff,James W. Dear	2023	2
4	Regular Acetaminophen Use and Blood Pressure in People With Hypertension: The PATH-BP Trial Circulation ·I. MacIntyre,Emma Turtle,Tariq E. Farrah,Catriona Graham,James W. Dear,David J. Webb,M.I.D. MCCALLUM,Vanessa Melville,Henry Fok,Jame McCrae,Ashish Sule,Thomas M. Caparrotta,Nicholas S. Kirkby,Jane A. Mitchell	2022	30
5	Cohort profile: the Scottish Diabetes Research Network national diabetes cohort – a population-based cohort of people with diabetes in Scotland BMJ Open ·Stuart J. McGurnaghan,Luke A. K. Blackbourn,Thomas M. Caparrotta,Joseph Mellor,Anna Barnett,Andrew Collier,Naveed Sattar,John McKnight,John R. Petrie,Sam Philip,Robert S. Lindsay,Katherine Hughes,David McAllister,Graham Leese,Ewan R. Pearson,Sarah H. Wild,Paul McKeigue,Helen M. Colhoun	2022	15
6	Large socioeconomic gap in period life expectancy and life years spent with complications of diabetes in the Scottish population with type 1 diabetes, 2013–2018 PLoS ONE ·Andreas Höhn,Stuart J. McGurnaghan,Thomas M. Caparrotta,Anita Jeyam,Joseph O’Reilly,Luke A. K. Blackbourn,Sara Hatam,Christian Dudel,Rosie J. Seaman,Joseph Mellor,Naveed Sattar,Rory J. McCrimmon,Brian Kennon,John R. Petrie,Sarah H. Wild,Paul McKeigue,Helen M. Colhoun,(unknown)	2022	4
7	The association of polypharmacy and high-risk drug classes with adverse health outcomes in the Scottish population with type 1 diabetes Diabetologia ·Andreas Höhn,Anita Jeyam,Thomas M. Caparrotta,Stuart J. McGurnaghan,Joseph O’Reilly,Luke A. K. Blackbourn,Rory J. McCrimmon,Graham Leese,John McKnight,Brian Kennon,Robert S. Lindsay,Naveed Sattar,Sarah H. Wild,Paul McKeigue,Helen M. Colhoun	2021	5
8	Development and validation of a cardiovascular risk prediction model in type 1 diabetes Diabetologia ·Stuart J. McGurnaghan,Paul McKeigue,Stephanie H. Read,Stefan Franzén,Ann‐Marie Svensson,Marco Colombo,Shona Livingstone,Bassam Farran,Thomas M. Caparrotta,Luke A. K. Blackbourn,Joseph Mellor,Ioanna Thoma,Naveed Sattar,Sarah H. Wild,Soffia Guðbjörnsdóttir,Helen M. Colhoun	2021	31
9	Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study Diabetes Care ·Joseph O’Reilly,Anita Jeyam,Thomas M. Caparrotta,Joseph Mellor,Andreas Höhn,Paul McKeigue,Stuart J. McGurnaghan,Luke A. K. Blackbourn,Rory J. McCrimmon,Sarah H. Wild,John R. Petrie,John McKnight,Brian Kennon,John Chalmers,Sam Phillip,Graham Leese,Robert S. Lindsay,Naveed Sattar,Fraser W. Gibb,Helen M. Colhoun	2021	16
10	Flash monitor initiation is associated with improvements in HbA1c levels and DKA rates among people with type 1 diabetes in Scotland: a retrospective nationwide observational study Diabetologia ·Anita Jeyam,Fraser W. Gibb,John McKnight,Joseph O’Reilly,Thomas M. Caparrotta,Andreas Höhn,Stuart J. McGurnaghan,Luke A. K. Blackbourn,Sara Hatam,Brian Kennon,Rory J. McCrimmon,Graham Leese,Sam Philip,Naveed Sattar,Paul McKeigue,Helen M. Colhoun	2021	19
11	Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies Diabetes Therapy ·Thomas M. Caparrotta,Andrew M. Greenhalgh,Karen Osinski,Robert M. Gifford,S. Moser,Sarah H. Wild,Rebecca M. Reynolds,David R. Webb,Helen M. Colhoun	2021	31
12	Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland Diabetologia ·Anita Jeyam,Fraser W. Gibb,John McKnight,Brian Kennon,Joseph O’Reilly,Thomas M. Caparrotta,Andreas Höhn,Stuart J. McGurnaghan,Luke A. K. Blackbourn,Sara Hatam,Rory J. McCrimmon,Graham Leese,Robert S. Lindsay,John R. Petrie,John Chalmers,Sam Philip,Sarah H. Wild,Naveed Sattar,Paul McKeigue,Helen M. Colhoun	2021	28
13	Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study BMC Medicine ·(unknown),Paul McKeigue,Sharon Kennedy,Amanda Weir,Jen Bishop,Stuart J. McGurnaghan,David McAllister,Chris Robertson,Rachael Wood,Nazir Lone,Janet Murray,Thomas M. Caparrotta,Alison Smith‐Palmer,David Goldberg,Jim McMenamin,Bruce Guthrie,Sharon Hutchinson,Helen M. Colhoun	2021	42
14	Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies Diabetes Therapy ·Thomas M. Caparrotta,Jack B. Templeton,Thomas A. Clay,Sarah H. Wild,Rebecca M. Reynolds,David R. Webb,Helen M. Colhoun	2021	19
15	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology–Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium–Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland Diabetes Care ·Thomas M. Caparrotta,Luke A. K. Blackbourn,Stuart J. McGurnaghan,John Chalmers,Robert S. Lindsay,Rory J. McCrimmon,John McKnight,Sarah H. Wild,John R. Petrie,Sam Philip,Paul McKeigue,David J. Webb,Naveed Sattar,Helen M. Colhoun	2020	14
16	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study PLoS Medicine ·Paul McKeigue,Amanda Weir,Jen Bishop,Stuart J. McGurnaghan,Sharon Kennedy,David McAllister,Chris Robertson,Rachael Wood,Nazir Lone,Janet Murray,Thomas M. Caparrotta,Alison Smith‐Palmer,David Goldberg,Jim McMenamin,Colin N. Ramsay,Sharon Hutchinson,Helen M. Colhoun,(unknown)	2020	44
17	Time trends in deaths before age 50 years in people with type 1 diabetes: a nationwide analysis from Scotland 2004–2017 Diabetologia ·Joseph O’Reilly,Luke A. K. Blackbourn,Thomas M. Caparrotta,Anita Jeyam,Brian Kennon,Graham Leese,Robert S. Lindsay,Rory J. McCrimmon,Stuart J. McGurnaghan,Paul McKeigue,John McKnight,John R. Petrie,Sam Philip,Naveed Sattar,Sarah H. Wild,Helen M. Colhoun	2020	10
18	The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study Diabetologia ·Stuart J. McGurnaghan,Liam Brierley,Thomas M. Caparrotta,Paul McKeigue,Luke A. K. Blackbourn,Sarah H. Wild,Graham Leese,Rory J. McCrimmon,John McKnight,Ewan R. Pearson,John R. Petrie,Naveed Sattar,Helen M. Colhoun	2019	30
19	Safety and Efficacy of the SNAP 12-hour Acetylcysteine Regimen for the Treatment of Paracetamol Overdose EClinicalMedicine ·Janice Pettie,Thomas M. Caparrotta,Robert W. Hunter,Emma Morrison,David M. Wood,Paul I. Dargan,Ruben Thanacoody,Simon H. L. Thomas,Muhammad E. M. O. Elamin,Ben Francis,David J. Webb,Euan A. Sandilands,Michael Eddleston,James W. Dear	2019	49
20	Are some people at increased risk of paracetamol-induced liver injury? A critical review of the literature European Journal of Clinical Pharmacology ·Thomas M. Caparrotta,Daniel J. Antoine,James W. Dear	2017	61

About Thomas M. Caparrotta

Thomas M. Caparrotta is a scholar working on Endocrinology, Diabetes and Metabolism, Pharmacology and Emergency Medicine, having authored 23 papers that have together received 583 indexed citations. Recurring topics across this work include Diabetes Management and Research (11 papers), Diabetes Treatment and Management (9 papers), Diabetes and associated disorders (4 papers), Metabolism, Diabetes, and Cancer (4 papers), Chronic Disease Management Strategies (3 papers), Poisoning and overdose treatments (3 papers), COVID-19 Clinical Research Studies (3 papers) and Drug-Induced Hepatotoxicity and Protection (3 papers). The work is most often cited by research in Pharmacology (153 citations), Endocrinology, Diabetes and Metabolism (231 citations) and Emergency Medicine (67 citations). Thomas M. Caparrotta has collaborated with scholars based in United Kingdom, Canada and United States. Frequent co-authors include James W. Dear, Helen M. Colhoun, Marc Evans, John Paul Thompson, James Coulson, Daniel J. Antoine, Paul McKeigue, Sarah H. Wild, Stuart J. McGurnaghan and Luke A. K. Blackbourn. Their work appears in journals such as Circulation, PLoS ONE and Diabetes Care.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact